Abstract
Agennix is developing recombinant human (rh) lactoferrin, a glycoprotein with antibiotic, anti-inflammatory and immunomodulatory activity, for the potential treatment of cancers, asthma and chronic wounds. rh Lactoferrin is currently undergoing phase II clinical trials.
MeSH terms
-
Aspergillus / genetics
-
Asthma / drug therapy*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Humans
-
Lactoferrin / genetics
-
Lactoferrin / pharmacokinetics*
-
Lactoferrin / therapeutic use*
-
Neoplasms / drug therapy*
-
Recombinant Proteins / genetics
-
Recombinant Proteins / pharmacokinetics
-
Recombinant Proteins / therapeutic use
-
Wound Healing / drug effects*
-
Wounds and Injuries / drug therapy*
Substances
-
Recombinant Proteins
-
Lactoferrin